Dextromethorphan is a widely used medication primarily employed as a cough suppressant for the symptomatic treatment of dry, non-productive coughs associated with conditions such as the common cold, upper respiratory tract infections, and throat irritation [1]. It functions centrally within the by acting on the cough center in the medulla oblongata, primarily through antagonism of the NMDA receptor, a key glutamate receptor involved in excitatory neurotransmission [2]. Despite its structural similarity to opioids, dextromethorphan lacks significant analgesic or respiratory depressant effects at therapeutic doses, distinguishing it from classical opioids like . It is commonly found in over-the-counter (OTC) medications such as , , , and various combination products that may also contain , , or [3]. While generally safe when used as directed, misuse or excessive intake can lead to serious adverse effects, including dissociative states, hallucinations, and potentially life-threatening complications such as , particularly when combined with other serotonergic agents like SSRIs or MAOIs [4]. The metabolism of dextromethorphan is primarily mediated by the CYP2D6 enzyme, and genetic polymorphisms in this system can significantly influence both efficacy and safety, leading to variable responses among individuals [5]. Emerging research suggests potential therapeutic applications beyond cough suppression, including use in —notably in combination with under the brand name —and possible benefits in reducing [6]. However, its recreational abuse, known as "robotripping," especially among adolescents, raises public health concerns due to risks of neurotoxicity, cognitive impairment, and psychiatric sequelae [7]. Regulatory agencies such as the FDA and the EMA have recognized these risks, prompting ongoing evaluation of safety measures and restrictions in certain populations, particularly children [8].

Pharmacological Mechanism and Neurochemical Actions

Dextromethorphan exerts its primary therapeutic effects through complex interactions within the , particularly via modulation of key neurotransmitter systems. Its pharmacological profile is distinct from classical opioids, relying instead on antagonism of excitatory pathways and interaction with specialized receptor systems to achieve cough suppression and other neurochemical effects [2].

Antagonism of the N-Methyl-D-Aspartate (NMDA) Receptor

The principal mechanism of action for dextromethorphan involves non-competitive antagonism of the NMDA receptor, a subtype of ionotropic glutamate receptor critical for excitatory neurotransmission [10]. By binding within the ion channel of the NMDA receptor, dextromethorphan blocks the influx of calcium ions (Ca²⁺), thereby reducing neuronal excitability in circuits involved in the cough reflex located in the medulla oblongata [11]. This antagonism dampens synaptic transmission and inhibits the propagation of signals that trigger coughing, making it effective against dry, non-productive coughs.

At higher, supratherapeutic doses, this NMDA receptor blockade becomes more pronounced, leading to dissociative and psychotomimetic effects similar to those of or phencyclidine (PCP) [10]. These effects include hallucinations, altered perception of time and space, and feelings of detachment from reality—phenomena commonly reported in recreational abuse known as "robotripping" [13]. The dose-dependent nature of these actions underscores the dual role of NMDA antagonism: therapeutic at low levels and psychoactive at high concentrations [14].

Interaction with Sigma-1 (σ1) Receptors

In addition to its action on NMDA receptors, dextromethorphan functions as an agonist at sigma-1 (σ1) receptors, which are intracellular chaperone proteins located primarily in the endoplasmic reticulum of neurons [15]. Activation of σ1 receptors modulates several cellular processes, including calcium signaling, neuroplasticity, and protection against oxidative stress [16]. These effects contribute to both neuroprotective properties and potential antidepressant activity.

Preclinical studies have demonstrated that the antidepressant-like effects of dextromethorphan are largely mediated through σ1 receptor activation, as these effects are abolished in genetically modified mice lacking the σ1 receptor gene [17]. This interaction enhances synaptic resilience and supports neuronal survival under conditions of metabolic or excitotoxic stress, suggesting a broader therapeutic potential beyond cough suppression [18].

Modulation of the Serotonergic System

Dextromethorphan also interacts with the (5-HT) system, albeit weakly, by inhibiting the reuptake of serotonin via the serotonin transporter (SERT) [10]. While this effect is less potent than that of selective serotonin reuptake inhibitors (SSRIs), it contributes to mood modulation and may underlie some of the drug’s off-label applications in psychiatric disorders. However, this property also introduces a significant clinical risk: when combined with other serotonergic agents such as SSRIs, MAOIs, or , dextromethorphan can precipitate , a potentially life-threatening condition characterized by hyperthermia, autonomic instability, neuromuscular hyperactivity, and altered mental status [20].

The risk is further amplified in individuals who are ultra-rapid metabolizers due to genetic polymorphisms in the CYP2D6 enzyme, as elevated plasma levels of dextromethorphan increase serotonergic tone [21]. Thus, while serotonergic modulation may enhance therapeutic outcomes in controlled settings, it necessitates careful evaluation in polypharmacy scenarios.

Neuroprotective and Dissociative Effects: Dual Outcomes of Shared Mechanisms

The same neurochemical mechanisms that confer therapeutic benefits also explain adverse and recreational effects. NMDA receptor antagonism not only suppresses cough but also provides neuroprotection by preventing excitotoxic neuronal death caused by excessive glutamate release—a process implicated in conditions such as stroke, traumatic brain injury, and neurodegenerative diseases [22]. By limiting calcium influx, dextromethorphan reduces activation of proteolytic enzymes and mitochondrial dysfunction, preserving cellular integrity [23].

Conversely, the same blockade leads to dissociative states at high doses, disrupting integrative brain functions and producing out-of-body experiences [24]. These effects are particularly pronounced in adolescents and young adults, who may misuse over-the-counter cough medications containing dextromethorphan for their hallucinogenic properties [25]. Chronic or recurrent use at such doses has been associated with long-term cognitive deficits, memory impairment, and persistent psychiatric symptoms, including psychosis [26].

Pharmacodynamic Synergy in Combination Therapy

The pharmacological rationale for combining dextromethorphan with —as seen in the FDA-approved formulation for treatment-resistant depression—relies on synergistic neurochemical actions. Bupropion inhibits the CYP2D6 enzyme, slowing the metabolism of dextromethorphan and increasing its bioavailability in the brain [27]. This allows lower doses of dextromethorphan to achieve clinically effective concentrations, enhancing both NMDA antagonism and σ1 receptor activation while minimizing side effects.

Simultaneously, bupropion’s own mechanism as a NDRI complements dextromethorphan’s action by boosting dopaminergic and noradrenergic transmission, which improves energy, motivation, and executive function—domains often impaired in major depressive disorder [28]. This multimodal approach represents a shift toward rapid-acting antidepressants that target multiple neurotransmitter systems, offering faster symptom relief compared to traditional monoaminergic drugs [29].

In summary, dextromethorphan’s pharmacological mechanism is multifaceted, involving antagonism of the NMDA receptor, activation of sigma-1 receptors, and modulation of serotonergic neurotransmission. These actions collectively account for its antitussive efficacy, dissociative potential, neuroprotective qualities, and emerging role in psychiatric therapeutics. Understanding these neurochemical interactions is essential for optimizing clinical use and mitigating risks associated with misuse or drug interactions.

Therapeutic Uses and Clinical Indications

Dextromethorphan is primarily indicated as a centrally acting for the symptomatic relief of dry, non-productive coughs. Its clinical utility stems from its ability to suppress the cough reflex without significantly affecting respiratory drive, making it a preferred alternative to traditional opioids like in many cases [1]. It is not recommended for productive coughs (those involving mucus or phlegm), as suppressing such coughs may interfere with the clearance of respiratory secretions [31].

Primary Use: Symptomatic Cough Suppression

The principal therapeutic application of dextromethorphan is in managing coughs associated with the , upper respiratory tract infections, and throat irritation. It achieves this by acting on the cough center located in the medulla oblongata of the [2]. By reducing the activity of this center, dextromethorphan effectively decreases the frequency and intensity of coughing episodes. Its widespread availability in over-the-counter (OTC) medications underscores its established role in self-care for minor respiratory symptoms [33].

Emerging Clinical Applications

Beyond its traditional role, dextromethorphan is being investigated for several novel therapeutic indications, reflecting its complex neuropharmacological profile. One of the most significant advancements is its use in the treatment of . In 2022, the FDA approved a combination formulation of dextromethorphan and under the brand name for the treatment of major depressive disorder in adults [34]. This combination leverages the pharmacokinetic interaction between the two drugs, where bupropion inhibits the CYP2D6 enzyme, thereby increasing the bioavailability and central nervous system exposure of dextromethorphan [35]. The antidepressant effect is attributed to dextromethorphan's dual action as an NMDA receptor antagonist and a agonist, mechanisms that promote neuroplasticity and have rapid-onset antidepressant effects similar to [36].

Another promising area of research involves the potential of dextromethorphan in mitigating . Preclinical studies have indicated that dextromethorphan can inhibit the deposition of collagen and slow the progression of lung scarring, suggesting a possible role in managing this serious and often fatal lung disease [37]. These findings open new avenues for repurposing this widely available medication for chronic respiratory conditions.

Use in Pediatric and Special Populations

The use of dextromethorphan in children requires careful consideration. It is generally not recommended for children under 4 years of age due to a lack of proven efficacy and safety data [1]. Many health authorities, including the , advise against the use of over-the-counter cough and cold medications in young children, recommending non-pharmacological measures such as hydration and honey (for children over 1 year) instead [39]. For older children, use should be cautious and supervised by a healthcare provider, with strict adherence to weight-based dosing guidelines.

In patients with pre-existing conditions, such as chronic respiratory diseases like or , dextromethorphan should be used with caution. Although it does not typically cause significant respiratory depression at therapeutic doses, the risk may be heightened in individuals with compromised respiratory function [40]. Similarly, patients with hepatic impairment may experience altered metabolism of the drug, increasing the risk of accumulation and toxicity, necessitating dose adjustments or avoidance [41].

Clinical Guidelines and Recommendations

Clinical guidelines generally support the use of dextromethorphan as a first-line option for acute, non-productive cough in adults, given its favorable safety profile when used as directed [42]. Its lack of significant analgesic effects and low potential for dependence compared to opioids make it a safer choice for short-term symptomatic management. However, its use is often limited to a few days, as prolonged cough may indicate a more serious underlying condition requiring medical evaluation. The integration of dextromethorphan into combination products with , , or allows for a multi-symptom approach to cold and flu treatment, although the efficacy of such combinations is sometimes debated [43].

Formulations and Brand Names

Dextromethorphan is available in a wide range of pharmaceutical formulations, reflecting its widespread use as an over-the-counter (OTC) antitussive. These formulations are designed to provide symptomatic relief for dry, non-productive coughs associated with conditions such as the common cold and upper respiratory tract infections [1]. The availability of multiple dosage forms allows for flexible administration tailored to patient age, preference, and clinical need.

Oral Formulations and Common Brand Names

The most prevalent formulations of dextromethorphan include syrups, drops, tablets, and lozenges. In Italy, several well-known brands contain dextromethorphan as the active ingredient, such as Bronchenolo Tosse, Aricodil Tosse, and Cinfatos, which are marketed as cough suppressants [45]. These products are typically available as syrups or lozenges, with some formulations combining dextromethorphan with other active ingredients like for enhanced expectorant effects [46].

Internationally, dextromethorphan is a key component in numerous OTC cold and cough remedies. Prominent global brands include Delsym, known for its extended-release syrup formulation, Robitussin, which offers various combinations targeting different symptoms, Vicks Dayquil Cough, and Coricidin HBP, a product specifically formulated for individuals with high blood pressure [3]. These products often combine dextromethorphan with , , or to address multiple symptoms of respiratory illness simultaneously [8].

Other European brands containing dextromethorphan include Acodin and Actifed, which are used for the symptomatic relief of cough and other respiratory symptoms [8]. These formulations underscore the integration of dextromethorphan into comprehensive treatment strategies across different markets.

Combination Products and Multi-Symptom Formulations

Many dextromethorphan-containing products are designed as multi-symptom formulations, combining the antitussive with other agents to provide broader symptom relief. For example, some syrups and capsules pair dextromethorphan with (paracetamol) for pain and fever reduction, or with or to relieve nasal congestion. These combination products are particularly popular during cold and flu season, offering convenience for patients seeking relief from multiple concurrent symptoms [3].

The inclusion of dextromethorphan in such products highlights its role within the broader landscape of and self-medication. However, this also necessitates careful patient education to avoid unintentional overdose, especially when multiple products containing the same active ingredient are used concurrently [33].

Availability and Regulatory Status

Dextromethorphan is generally available without a prescription in most countries, including the United States and many European nations, where it is classified as a non-prescription medication [33]. In Italy, it is sold over the counter under various brand names such as Destrometorfano Bromidrato Sella and Destrometorfano Bromidrato Farmakopea, available in drop form for precise dosing [53]. The European Medicines Agency (EMA) has documented the national authorization of numerous dextromethorphan-containing medicines across EU member states, affirming its established therapeutic role [8].

Adverse Effects and Safety Profile

Dextromethorphan is generally considered safe and well-tolerated when used at recommended therapeutic doses for the symptomatic relief of dry, non-productive cough. However, its safety profile is highly dose-dependent, and misuse or excessive intake can lead to a wide range of adverse effects, from mild and transient symptoms to life-threatening complications. The risk of adverse reactions is further influenced by individual factors such as age, pre-existing medical conditions, genetic polymorphisms in drug-metabolizing enzymes like , and concomitant use of other medications.

Common and Mild Adverse Effects

At standard therapeutic doses—typically 10–20 mg every 4–8 hours, not exceeding 120 mg per day in adults—dextromethorphan is associated with a number of generally mild and self-limiting side effects. The most frequently reported include , , , , and gastrointestinal disturbances such as abdominal discomfort, vomiting, or constipation [55]. Additional common effects may include dry mouth, mild confusion, and occasional nervousness or agitation. Skin-related reactions such as pruritus or mild rashes have also been documented, though less frequently [1]. These effects are primarily attributed to the drug’s central action on the and tend to resolve either with continued use or upon discontinuation of the medication [57].

Serious Adverse Effects and Overdose Risks

In cases of overdose or recreational abuse, particularly at doses exceeding 200–300 mg, dextromethorphan can produce severe and potentially fatal adverse effects. The most concerning complications include seizures, coma, respiratory depression, hyperthermia, tachycardia, and profound alterations in mental status [58]. Doses above 1500 mg have been associated with fatalities, although the threshold for toxicity varies significantly among individuals due to differences in metabolism and drug interactions [59].

One of the most serious risks associated with high-dose dextromethorphan use is the development of , a potentially life-threatening condition caused by excessive serotonergic activity in the central and peripheral nervous systems. This risk is significantly heightened when dextromethorphan is combined with other serotonergic agents such as SSRIs (e.g., fluoxetine, sertralina), SNRIs, or MAOIs [21]. Symptoms of serotonin syndrome include agitation, confusion, muscle rigidity, hyperreflexia, tremors, hyperthermia, diaphoresis, and autonomic instability [20]. The condition can progress rapidly to multi-organ failure if not promptly recognized and treated [62].

Dissociative and Psychotomimetic Effects

A hallmark of dextromethorphan abuse, particularly in the context of "robotripping," is the emergence of dissociative and psychotomimetic effects. These are primarily mediated through the drug’s action as a non-competitive antagonist of the NMDA receptor, a mechanism shared with dissociative anesthetics like ketamine and phencyclidine (PCP) [2]. At high doses, this antagonism leads to profound alterations in perception, including visual and auditory hallucinations, distortions of time and space, depersonalization, derealization, and states of confusion or delirium [10]. Users often describe these experiences in "plateau" stages, with increasing dose correlating to escalating levels of dissociation, culminating in a near-comatose state at the highest levels [14].

These effects are not only dangerous in the acute setting but also raise concerns about long-term neurological and psychiatric consequences. Chronic or recurrent abuse of dextromethorphan has been linked to persistent cognitive deficits, including impairments in memory, attention, and executive function [26]. Neuroimaging and histological studies in animal models have shown that high-dose exposure can lead to structural brain damage, such as the formation of myelinoid bodies and mitochondrial dysfunction, indicative of neurotoxicity [67].

Long-Term Cognitive and Mental Health Consequences

Prolonged or repeated use of dextromethorphan at supratherapeutic doses poses significant risks to mental health, particularly among adolescents and young adults whose brains are still undergoing development. Clinical evidence suggests that chronic abuse can trigger or exacerbate psychiatric disorders, including persistent psychosis, severe anxiety, and major depressive disorder [68]. In vulnerable individuals, especially those with a genetic predisposition to psychiatric illness, dextromethorphan abuse may act as a precipitating factor for psychotic episodes that persist even after cessation of use [69].

Moreover, the drug has the potential to induce psychological and physical dependence, with users reporting withdrawal symptoms such as cravings, insomnia, irritability, and anxiety upon discontinuation [70]. The recreational use of dextromethorphan is often associated with comorbid substance use, risk-taking behaviors, and social dysfunction, further compounding its negative impact on overall well-being [71].

Risk Factors and Vulnerable Populations

Certain populations are at increased risk for adverse effects from dextromethorphan. The use of the drug in children under 4 years of age is not recommended due to a lack of proven efficacy and concerns about safety, including the potential for respiratory depression [1]. In pediatric patients, especially those under 6, non-pharmacological approaches such as hydration and honey (for children over 1 year) are often preferred [73].

Patients with pre-existing conditions such as chronic respiratory diseases (e.g., , ), hepatic impairment, or cardiovascular disorders require special caution. Impaired liver function can lead to reduced metabolism of dextromethorphan, increasing the risk of drug accumulation and toxicity [41]. Similarly, individuals who are poor metabolizers due to genetic variations in the enzyme are at higher risk of adverse effects even at standard doses, as they exhibit significantly elevated plasma concentrations of the parent drug [75].

Prevention and Clinical Management

Preventing adverse outcomes associated with dextromethorphan requires a multifaceted approach, including patient education, careful screening for drug interactions, and monitoring in high-risk individuals. Public health initiatives, particularly in school and community settings, have proven effective in raising awareness about the dangers of "robotripping" and the misconception that over-the-counter medications are inherently safe [7]. Programs that use peer-led education, real-life case studies, and digital outreach (e.g., the #MentreScrolli campaign) have been particularly impactful in changing adolescent perceptions [77].

In cases of acute toxicity, management is primarily supportive and symptomatic. Immediate interventions include airway protection, cardiovascular monitoring, and administration of benzodiazepines to control agitation, seizures, or muscle rigidity [20]. For serotonin syndrome, specific treatment may include the use of , a 5-HT2A receptor antagonist, as an antidote [62]. Prompt consultation with a poison control center or toxicologist is strongly advised in all cases of suspected overdose [80].

Drug Interactions and Contraindications

Dextromethorphan, while widely available over-the-counter and generally safe at recommended doses, presents significant risks when used in combination with certain medications or in patients with specific medical conditions. Its complex pharmacological profile necessitates careful consideration of potential drug interactions and contraindications to prevent serious adverse events, including , , and life-threatening arrhythmias. Understanding these interactions is critical for both healthcare providers and patients, particularly given the drug’s accessibility and potential for misuse.

Major Drug Interactions

Serotonergic Agents and Risk of Serotonin Syndrome

One of the most critical interactions involves the concomitant use of dextromethorphan with other , which significantly increases the risk of developing serotonin syndrome, a potentially fatal condition caused by excessive serotonergic activity in the central nervous system. Dextromethorphan itself possesses weak serotonin reuptake inhibitory properties, and at high doses, it can act as a serotonin agonist at 5-HT2A and 5-HT3 receptors. When combined with potent serotonergic drugs, this effect is amplified [21].

High-risk combinations include:

  • Selective serotonin reuptake inhibitors (SSRIs) such as , , and [82].
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs) like and .
  • Monoamine oxidase inhibitors (MAOIs) such as and the antibiotic , which has MAOI activity [53].
  • Other antidepressants including , , and [84].

Symptoms of serotonin syndrome include agitation, confusion, hyperthermia, diaphoresis, tremors, hyperreflexia, and tachycardia. In severe cases, it can progress to seizures, coma, and multi-organ failure [85]. The combination of dextromethorphan with fluoxetine or citalopram has been clinically documented to trigger serotonin syndrome, underscoring the need for avoidance or close monitoring [86].

Central Nervous System Depressants

Dextromethorphan has sedative effects due to its action on the . When used with other CNS depressants, it can potentiate sedation, dizziness, cognitive impairment, and, in extreme cases, respiratory depression. This interaction is particularly dangerous in vulnerable populations such as the elderly or those with pre-existing respiratory compromise.

Agents to avoid or use with caution include:

  • Benzodiazepines such as and .
  • Barbiturates.
  • Sedating antihistamines like and [87].
  • Alcohol (ethanol), which not only enhances sedation but also increases the risk of respiratory depression and altered mental status [88].

QT Interval-Prolonging Medications

Dextromethorphan has been associated with prolongation of the QT interval on the electrocardiogram, increasing the risk of serious ventricular arrhythmias such as torsades de pointes. This risk is magnified when dextromethorphan is co-administered with other drugs that also prolong the QT interval, including certain , (e.g., ), and like or [89].

CYP2D6 Inhibitors and Altered Metabolism

The metabolism of dextromethorphan is primarily mediated by the cytochrome P450 CYP2D6 enzyme, which converts it into its active metabolite, dextrorphan. Inhibitors of CYP2D6 can significantly increase plasma concentrations of dextromethorphan, leading to enhanced pharmacological effects and a higher risk of toxicity, even at therapeutic doses.

Key CYP2D6 inhibitors include:

  • Paroxetine
  • Fluoxetine
  • Quinidine
  • Terbinafine

These interactions can mimic the effects seen in poor metabolizers due to genetic polymorphisms, resulting in elevated dextromethorphan levels and increased central nervous system side effects such as confusion, hallucinations, and psychomotor agitation [90].

Contraindications

Dextromethorphan is contraindicated in several patient populations and clinical scenarios due to the risk of severe adverse outcomes.

Hypersensitivity

The drug is contraindicated in patients with known hypersensitivity to dextromethorphan or any of the excipients in the formulation [91].

Concomitant Use with MAOIs

The use of dextromethorphan is strictly contraindicated within 14 days of discontinuing treatment with MAOIs. This restriction is due to the heightened risk of serotonin syndrome and hypertensive crisis resulting from the synergistic increase in serotonin levels [92].

Pre-Existing Medical Conditions

Special caution is required in patients with certain underlying conditions:

  • Chronic respiratory diseases such as or , where suppression of the cough reflex may impair clearance of secretions and increase the risk of respiratory complications, including respiratory depression in overdose scenarios [40].
  • Hepatic impairment, as reduced liver function can impair the metabolism of dextromethorphan, leading to drug accumulation and increased toxicity risk. Caution is also warranted when used with other such as [41].

Special Populations

Pediatric Use

The use of dextromethorphan in children requires particular vigilance. It is not recommended in children under 4 years of age, and its use in children aged 4–6 should be approached with caution due to limited evidence of efficacy and safety [1]. The and other health authorities recommend non-pharmacological measures such as hydration and honey (for children over 1 year) as first-line approaches for cough in young children [39]. The Italian Medicines Agency (AIFA) has implemented monitoring and restrictions on dextromethorphan-containing products in pediatric populations in line with international guidelines [97].

Pregnancy and Lactation

Dextromethorphan should be used during pregnancy and breastfeeding only if clearly needed and under medical supervision, as its safety profile in these populations is not fully established [91].

Other Substances to Avoid

In addition to prescription medications, several non-prescription substances and behaviors can exacerbate risks:

  • Alcohol consumption should be avoided due to additive CNS depression [88].
  • Psychoactive substances or recreational drugs can amplify the dissociative and hallucinogenic effects of dextromethorphan, increasing the risk of overdose and psychiatric sequelae [2].
  • Over-the-counter combination products containing dextromethorphan and other active ingredients (e.g., acetaminophen, antihistamines) pose additional risks of hepatotoxicity, anticholinergic effects, and cumulative CNS depression when taken in excess.

Clinical Recommendations

Given the extensive interaction profile—approximately 340 known drug interactions, with 75 classified as major—it is imperative that patients consult a or before using dextromethorphan, especially if they are already taking medications for psychiatric, neurological, or cardiovascular conditions [90]. Reading the product label and adhering strictly to dosing instructions are essential to minimize risks. In cases of suspected interaction or overdose, immediate medical attention and consultation with a are critical [80].

Pharmacogenomics and Metabolism via CYP2D6

The metabolism of dextromethorphan is primarily mediated by the hepatic enzyme CYP2D6, a critical component of the phase I metabolic system responsible for the biotransformation of numerous medications [5]. This enzyme catalyzes the O-demethylation of dextromethorphan into its primary active metabolite, dextrorphan, which exhibits enhanced antagonistic activity at the NMDA receptor and contributes to both therapeutic and psychoactive effects [104]. However, the activity of CYP2D6 is highly variable among individuals due to extensive genetic polymorphism in the CYP2D6 gene, which contains over 170 known allelic variants (e.g., CYP2D6*3, *4, *5, *6) that define distinct metabolic phenotypes [5].

Genetic Polymorphisms and Metabolic Phenotypes

Individuals are classified into four main metabolic phenotypes based on their CYP2D6 genotype: poor metabolizers (PM), intermediate metabolizers (IM), normal (extensive) metabolizers (NM), and ultrarapid metabolizers (UM) [5]. Poor metabolizers possess little to no functional CYP2D6 enzyme activity, leading to significantly reduced conversion of dextromethorphan to dextrorphan. This results in systemic accumulation of the parent compound, with plasma concentrations up to five times higher than those observed in normal metabolizers following standard therapeutic doses [75]. Consequently, PMs are at increased risk of central nervous system (CNS)-related adverse effects such as excessive sedation, dizziness, confusion, hallucinations, and even neurotoxic or psychotic symptoms, even at recommended dosages [108].

In contrast, ultrarapid metabolizers—often carrying duplicated or amplified CYP2D6 alleles (e.g., CYP2D6*2xN)—rapidly and extensively convert dextromethorphan into dextrorphan [109]. This accelerated metabolism can lead to elevated levels of the active metabolite, potentially intensifying dissociative and psychotropic effects, particularly at high or recreational doses. Simultaneously, the rapid clearance of the parent drug may shorten the duration of antitussive action, compromising therapeutic efficacy [110].

Clinical Implications and Drug Interactions

The variability in CYP2D6 activity has significant clinical implications for both the safety and effectiveness of dextromethorphan therapy. Pharmacogenomic testing for CYP2D6 status can help identify patients at risk of suboptimal response or toxicity, enabling personalized dosing strategies [111]. This is particularly relevant in vulnerable populations such as pediatric and geriatric patients, or in individuals with unexplained adverse reactions.

Moreover, the presence of pharmacological inhibitors of CYP2D6 can induce a "phenocopy" of the poor metabolizer phenotype, even in genetically normal individuals. Potent inhibitors such as , , , and significantly reduce the enzyme’s ability to metabolize dextromethorphan, leading to increased plasma concentrations of the parent drug and a heightened risk of CNS toxicity [112]. This interaction not only elevates the potential for sedation, cognitive impairment, and hallucinations but may also increase the risk of , especially when dextromethorphan is co-administered with other serotonergic agents like SSRIs or SNRIs [113].

Therapeutic Monitoring and Personalized Medicine

Given these pharmacogenomic influences, the use of dextromethorphan exemplifies the importance of in optimizing drug therapy. While routine genotyping is not currently standard practice for over-the-counter use, awareness of CYP2D6 polymorphism is crucial in clinical settings where dextromethorphan is used therapeutically or in combination regimens. Physiologically based pharmacokinetic (PBPK) models are increasingly being employed to predict the impact of genetic and environmental factors on dextromethorphan disposition, supporting more precise dosing approaches [5].

In summary, the pharmacogenomics of CYP2D6 plays a pivotal role in determining the metabolic fate, clinical efficacy, and safety profile of dextromethorphan. Understanding these genetic and pharmacological influences enables healthcare providers to mitigate risks associated with variable drug response and supports the broader integration of into everyday clinical decision-making [115].

Recreational Use and Abuse Potential

Dextromethorphan (DXM) is widely recognized not only for its therapeutic role as a but also for its potential for recreational misuse, particularly among adolescents and young adults. The phenomenon, commonly known as "robotripping," involves the consumption of excessive amounts of over-the-counter (OTC) cough medicines containing dextromethorphan to achieve psychoactive effects [7]. This form of substance abuse has raised significant public health concerns due to the dissociative, hallucinogenic, and potentially neurotoxic effects associated with high-dose use.

Mechanisms Underlying Recreational Effects

The psychoactive properties of dextromethorphan at supratherapeutic doses are primarily attributed to its action as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a key component of the in the [2]. This mechanism is shared with dissociative anesthetics such as and , explaining the similar subjective experiences reported by users [118]. At high doses, dextrometorfano disrupts normal excitatory neurotransmission, leading to states of dissociation, altered perception of time and space, and out-of-body experiences.

Additionally, dextromethorphan acts as an agonist at sigma-1 (σ1) receptors, which modulate neuronal signaling, calcium homeostasis, and neuroplasticity [16]. Activation of these receptors contributes to the drug’s psychotomimetic effects and may enhance its dissociative profile. The combination of NMDA antagonism and sigma-1 receptor agonism underpins the dose-dependent progression of effects, often described in user communities as “plateaus,” ranging from mild stimulation to profound hallucinations and near-comatose states [14].

Patterns and Prevalence of Abuse

Recreational use of dextrometorfano typically involves ingesting multiple doses of OTC products such as , , or other cough syrups far exceeding recommended therapeutic levels—often 10 to 30 times the standard dose [25]. The accessibility, low cost, and legal status of these medications make them particularly attractive to adolescents experimenting with substances. According to epidemiological data, approximately 6.9% of U.S. adolescents have reported using DXM-containing products for non-medical purposes [122].

Acute Risks and Toxicity

High-dose dextromethorfano use poses serious acute health risks. Common symptoms of overdose include confusion, agitation, tachycardia, hypertension, nausea, and ataxia. More severe complications include seizures, coma, respiratory depression, and life-threatening serotonin syndrome, particularly when DXM is combined with other serotonergic agents such as or [20]. The risk is heightened due to DXM’s weak inhibition of serotonin reuptake, which, when amplified by other drugs or genetic factors, can lead to excessive serotonergic activity.

Moreover, many OTC cough formulations contain additional active ingredients such as , , or . Ingesting large quantities of these combination products increases the risk of hepatotoxicity, anticholinergic delirium, and cardiovascular complications [124].

Long-Term Cognitive and Psychiatric Consequences

Chronic or recurrent use of dextromethorfano at high doses has been linked to lasting impairments in mental health and cognitive function. Prolonged exposure to NMDA antagonism can result in neurotoxicity, including the formation of myelinoid bodies and mitochondrial dysfunction, which may contribute to persistent deficits in memory, attention, and executive function [67]. These effects are especially concerning in adolescents, whose brains are still undergoing critical developmental processes [126].

Clinically, chronic DXM abuse has been associated with the onset of psychotic disorders, including hallucinations, paranoia, and delusional thinking, sometimes persisting even after cessation of use. This phenomenon has led some clinicians to refer to DXM as the “poor man’s psychosis” due to its ability to mimic symptoms of schizophrenia [24]. Additionally, users may develop psychological dependence, with withdrawal symptoms such as anxiety, insomnia, and cravings reported upon discontinuation [70].

Clinical Differentiation from Other Dissociative Substances

While dextromethorfano shares pharmacological similarities with other dissociatives like ketamine and PCP, it differs in several clinically relevant aspects. Unlike ketamine, which has a rapid onset and short duration (30–60 minutes), DXM effects can last 4–6 hours, increasing the window for adverse events. Furthermore, DXM carries a higher risk of serotonin syndrome due to its serotonergic activity—a risk less pronounced with ketamine or PCP [129]. Its availability as an OTC medication also distinguishes it from controlled substances, contributing to a false perception of safety among users.

Prevention and Educational Interventions

Effective prevention strategies focus on education and awareness, particularly in school and community settings. Programs that provide accurate, science-based information about the neurobiological risks of DXM abuse—such as cognitive decline and permanent brain damage—have proven more effective than fear-based messaging [130]. Initiatives like the Italian government’s “Fermati. Pensaci un minuto” campaign use relatable language and peer testimonials to encourage critical thinking before substance use [131].

Pharmacists also play a crucial role in monitoring suspicious purchasing patterns and providing counseling to at-risk individuals. In some jurisdictions, restrictions on the sale of DXM-containing products to minors have been implemented to reduce accessibility [132]. Digital outreach, such as the #MentreScrolli campaign by Rai Scuola, leverages social media to engage youth in discussions about substance use and mental health [77].

Management of DXM Use Disorder

Treatment for dextromethorfano use disorder requires a multidimensional approach. Acute intoxication is managed with supportive care, including benzodiazepines for agitation or seizures, active cooling for hyperthermia, and discontinuation of all serotonergic agents in cases of suspected serotonin syndrome. The antidote cyproheptadine, a 5-HT2A receptor antagonist, may be used in moderate to severe cases [20].

For long-term recovery, evidence supports the use of cognitive-behavioral therapy (CBT) to address maladaptive thought patterns and improve coping skills. Motivational interviewing (MI) is particularly effective with adolescents, helping to enhance intrinsic motivation for change [135]. Family therapy is also essential, especially when underlying trauma, anxiety, or depression contributes to substance use. Given the high rate of comorbidity with psychiatric conditions, integrated treatment for dual diagnosis is recommended [136].

Emerging Therapeutic Applications

Dextromethorphan, long recognized for its role as a centrally acting , is increasingly being investigated for a range of novel therapeutic applications beyond cough suppression. These emerging uses leverage its complex pharmacological profile, particularly its actions on the , , and , opening new avenues for treating neuropsychiatric and neurodegenerative conditions [6].

Treatment of Treatment-Resistant Depression

One of the most significant advances in dextromethorphan’s therapeutic repurposing is its use in the treatment of (TRD) and major depressive disorder (MDD). This application is realized through a fixed-dose combination with , marketed under the brand name . The rationale for this combination lies in both pharmacokinetic and pharmacodynamic synergy. Bupropion acts as a potent inhibitor of the CYP2D6 enzyme, which is responsible for the rapid metabolism of dextromethorphan into its inactive metabolite, dextrorphan. By inhibiting CYP2D6, bupropion significantly increases the systemic bioavailability and half-life of dextromethorphan, allowing it to reach therapeutic concentrations in the [138].

Pharmacodynamically, dextromethorphan exerts its antidepressant effects primarily through two key mechanisms: antagonism of the NMDA receptor and agonism of the . NMDA receptor antagonism reduces glutamatergic excitotoxicity and promotes synaptic plasticity, a mechanism shared with rapid-acting antidepressants like . Simultaneously, activation of sigma-1 receptors enhances neuroprotection, modulates calcium signaling, and supports neuronal survival and plasticity. Clinical trials have demonstrated that the dextromethorphan-bupropion combination produces a rapid onset of antidepressant action, with significant symptom improvement observed as early as one week into treatment, and higher remission rates compared to placebo in patients with MDD [29]. This led to its approval by the FDA in 2022 for the treatment of MDD in adults [34].

Potential in Bipolar Depression

While the dextromethorphan-bupropion combination is approved for MDD, its potential utility in bipolar depression is an area of active investigation. Although no large-scale clinical trials have yet been published specifically for bipolar disorder, the underlying neurobiological mechanisms—modulation of glutamatergic transmission via NMDA receptor antagonism and sigma-1 receptor activation—are considered relevant to the pathophysiology of bipolar depression. A clinical trial registered on ClinicalTrials.gov (NCT01188265) explored the adjunctive use of dextromethorphan in bipolar disorder, indicating preliminary interest, though comprehensive results remain unpublished [141]. Caution is warranted, however, as the dopaminergic effects of bupropion carry a theoretical risk of inducing manic or hypomanic episodes in individuals with bipolar disorder, necessitating careful patient selection and concomitant use of mood stabilizers.

Neuroprotective Effects and Neurodegenerative Disorders

The NMDA receptor antagonism and sigma-1 receptor agonism of dextromethorphan also underlie its potential neuroprotective properties. Excessive activation of NMDA receptors leads to calcium influx and excitotoxic neuronal death, a process implicated in conditions such as , , and neurodegenerative diseases like . By blocking this pathway, dextromethorphan may help protect neurons from damage. Preclinical studies have shown that dextromethorphan reduces neuronal injury in models of brain trauma and ischemia, and it has been explored as a potential therapeutic agent in (ALS), where it is combined with quinidine to prolong its action by inhibiting CYP2D6 metabolism [92]. This combination, known as , is approved for the treatment of pseudobulbar affect, a condition characterized by uncontrollable laughing or crying, often seen in ALS and other neurological disorders.

Emerging Role in Pulmonary Fibrosis

Beyond neuropsychiatry, recent research has uncovered a potential role for dextromethorphan in the treatment of , a chronic and progressive lung disease characterized by excessive collagen deposition and scarring of lung tissue. A 2024 study highlighted that dextromethorphan can inhibit the activation of fibroblasts and reduce collagen production in lung tissue, suggesting a direct antifibrotic effect [37]. This discovery positions dextromethorphan as a promising candidate for repurposing in respiratory medicine, potentially offering a new, accessible treatment option for a condition with limited therapeutic alternatives. Further clinical studies are needed to validate these preclinical findings and determine optimal dosing and safety in patients with pulmonary fibrosis [144].

Dissociative and Psychedelic Effects in Therapeutic Contexts

At high doses, dextromethorphan produces dissociative and psychedelic effects due to profound NMDA receptor blockade, leading to states of derealization and altered consciousness similar to those induced by ketamine or (PCP) [10]. While this profile is associated with recreational abuse ("robotripping"), it also raises interest in its potential for use in psychedelic-assisted therapy. The dissociative state may facilitate psychological insights and emotional processing, mechanisms that are being harnessed in experimental therapies for conditions such as (PTSD) and end-of-life anxiety. However, this application remains highly experimental and is complicated by the risk of adverse psychological reactions and the potential for abuse. Rigorous clinical trials are required to assess the safety, efficacy, and ethical considerations of using dextromethorphan in this context.

In summary, the emerging therapeutic applications of dextromethorphan reflect a paradigm shift from a simple cough suppressant to a multifaceted agent with significant potential in psychiatry and neurology. Its actions on the , , and —particularly when combined with metabolic inhibitors like bupropion—offer new hope for patients with treatment-resistant conditions. Ongoing research continues to explore its utility in , , , and even psychedelic therapy, underscoring the importance of pharmacovigilance and further clinical validation to ensure safe and effective use.

Regulatory Guidelines and Public Health Considerations

The widespread availability and therapeutic utility of dextromethorphan as an over-the-counter (OTC) antitussive are balanced by significant public health concerns, particularly related to misuse, abuse, and potential drug interactions. Regulatory agencies worldwide, including the FDA and the EMA, have implemented and continue to evaluate guidelines to ensure its safe use, especially among vulnerable populations such as adolescents and individuals with preexisting medical conditions [8].

Age-Based Restrictions and Pediatric Use

A key regulatory focus is the use of dextromethorphan in children. Due to limited evidence of efficacy and concerns about adverse effects, many health authorities advise against its use in young children. The American Academy of Pediatrics and similar organizations recommend avoiding antitussives containing dextromethorphan in children under six years of age, and often extend this caution to those under twelve [39]. In the United States, the FDA has not approved dextromethorphan for use in children under four years old [1]. Similarly, the AIFA in Italy has issued restrictions and ongoing monitoring for dextromethorphan-containing products in pediatric populations, aligning with international best practices [97]. For older children, dosing must be carefully adjusted according to body weight, and use should occur only under medical supervision when necessary.

Abuse Prevention and the "Robotripping" Phenomenon

The recreational misuse of dextromethorphan, known as "robotripping," is a major public health issue, particularly among adolescents. This practice involves consuming large quantities of OTC cough medicines to achieve dissociative and hallucinogenic effects [7]. The ease of access to these products makes prevention challenging. Public health campaigns, such as Italy's "Fermati. Pensaci un minuto" and "Non farlo – Chiediti perché," aim to raise awareness among youth about the dangers of substance abuse [131]. Educational programs in schools that incorporate cognitive-behavioral strategies have proven effective in modifying risk perceptions and reducing impulsive drug use [152].

Regulatory Actions and Sales Restrictions

In response to abuse, several jurisdictions have implemented sales restrictions. Some U.S. states require purchasers to be at least 18 years old and to present identification when buying dextromethorphan-containing products. In Italy, regulatory updates have included the inclusion of dextromethorphan in controlled substance tables, reflecting its potential for misuse [153]. The EMA has published a comprehensive list of nationally authorized medicinal products containing dextromethorphan, facilitating cross-border monitoring and policy coordination [8]. These measures aim to balance patient access for legitimate medical use with the need to curb recreational abuse.

Pharmacogenomic Considerations and Personalized Medicine

The role of in dextromethorphan safety is increasingly recognized. Genetic polymorphisms in the CYP2D6 enzyme significantly influence how individuals metabolize the drug. Metabolizers who are poor (PM) may experience toxic accumulation of dextromethorphan even at standard doses, leading to severe central nervous system effects [5]. Conversely, ultrarapid metabolizers (UM) may convert the drug too quickly, reducing its efficacy. While routine genetic testing is not currently recommended before OTC use, awareness of this variability is crucial for clinicians, especially when managing patients on multiple medications or those with unexplained adverse reactions. This highlights the growing importance of in optimizing drug safety.

Drug Interaction Warnings and Labeling Requirements

Regulatory guidelines emphasize the critical importance of avoiding dangerous drug interactions. Dextromethorphan carries a significant risk of when combined with SSRIs, SNRIs, or MAOIs [90]. It can also potentiate the sedative effects of other central nervous system depressants, such as and alcohol, increasing the risk of respiratory depression [88]. As a result, product labeling is required to include clear warnings about these interactions. Pharmacists play a vital role in counseling patients, especially those on complex medication regimens, about the risks of combining OTC products with prescription drugs [132].

Long-Term Cognitive and Mental Health Risks

Chronic or recurrent abuse of dextromethorphan at high doses is associated with serious long-term consequences. Neuroimaging and clinical studies suggest that prolonged use can lead to structural brain changes, including the formation of myeloid bodies and mitochondrial dysfunction, potentially resulting in persistent cognitive deficits, memory impairment, and executive function decline [67]. There is also a documented risk of inducing or exacerbating psychiatric conditions, including psychosis, depression, and anxiety disorders, particularly in adolescents whose brains are still developing [26]. These findings underscore the need for early intervention and comprehensive treatment strategies that address both substance use and underlying mental health issues, often requiring a multidisciplinary approach involving and .

References